Medicine and Dentistry
Patient
100%
Glioblastoma
82%
Immune Checkpoint Inhibitor
74%
Inpatient
65%
Therapeutic Procedure
56%
Brain Metastasis
47%
Immunotherapy
40%
Combination Therapy
39%
Cancer
38%
Ganglioglioma
33%
Nivolumab
33%
COVID-19
33%
Oligoastrocytoma
33%
Bevacizumab
33%
Breast Cancer
33%
Sacituzumab Govitecan
33%
Biological Marker
31%
Lung Cancer
30%
Lymphadenopathy
26%
Survival
26%
Epidermal Growth Factor Receptor
25%
T Lymphocyte
23%
Brain Tumor
22%
Non Small Cell Lung Cancer
22%
Chemotherapeutic Agent
19%
Drug
19%
Mutant
18%
Patient Population
18%
Glucocorticoid
16%
Immune Response
16%
Comprehension
16%
Solid Malignant Neoplasm
16%
Diseases
14%
Neoplasm
14%
Case Report
13%
Clear Cell
12%
Kidney Metastasis
12%
Histology
12%
Medulloblastoma
11%
Aptitude
11%
Adverse Event
11%
Exon
11%
Monotherapy
10%
Mortality
10%
DNA Mismatch Repair
8%
Systemic Administration
8%
Tumor Microenvironment
8%
Corticosteroid
8%
Organ
8%
Programmed Death 1 Receptor
8%
Pharmacology, Toxicology and Pharmaceutical Science
Programmed Death-Ligand 1
41%
Atezolizumab
33%
Malignant Neoplasm
33%
Astrocytoma
33%
Bevacizumab
33%
Sacituzumab Govitecan
33%
Brain Metastasis
33%
Non Small Cell Lung Cancer
30%
Immunotherapy
30%
Biological Marker
28%
Epidermal Growth Factor Receptor
25%
Survival
18%
Chemotherapy
16%
Antibody
16%
Glucocorticoid
16%
Glioblastoma
16%
Brain Metastasis
14%
Drug
11%
Toxicity
11%
Programmed Death 1 Ligand 1
8%
Clotiazepam
8%
Solid Malignant Neoplasm
8%
Bladder Cancer
8%
Immunoglobulin G1
8%
Monoclonal Antibody
8%
DNA
8%
Neoplasm
8%
Epidermal Growth Factor Receptor Kinase Inhibitor
7%
Protein Tyrosine Kinase Inhibitor
7%
Clinical Trial
6%
Monotherapy
6%
